Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compass Therapeutics (CMPX) Current Leases (2022 - 2026)

Compass Therapeutics' Current Leases history spans 5 years, with the latest figure at $1.4 million for Q1 2026.

  • On a quarterly basis, Current Leases rose 1159.63% to $1.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.4 million, a 1159.63% increase, with the full-year FY2025 number at $1.0 million, up 195.86% from a year prior.
  • Current Leases hit $1.4 million in Q1 2026 for Compass Therapeutics, up from $1.0 million in the prior quarter.
  • Over the last five years, Current Leases for CMPX hit a ceiling of $1.4 million in Q1 2026 and a floor of $109000.0 in Q1 2025.
  • Historically, Current Leases has averaged $906928.6 across 5 years, with a median of $1.1 million in 2022.
  • Biggest five-year swings in Current Leases: crashed 91.09% in 2025 and later surged 1159.63% in 2026.
  • Tracing CMPX's Current Leases over 5 years: stood at $1.1 million in 2022, then rose by 9.12% to $1.2 million in 2023, then crashed by 71.76% to $338000.0 in 2024, then soared by 195.86% to $1.0 million in 2025, then skyrocketed by 37.3% to $1.4 million in 2026.
  • Business Quant data shows Current Leases for CMPX at $1.4 million in Q1 2026, $1.0 million in Q4 2025, and $1.0 million in Q3 2025.